Sinovac cuts full-year revenue forecast

Sinovac Biotech shares fell 10 percent Monday, a day after the vaccine manufacturer cut its full-year revenue forecast for the second time, citing continued weakness in Chinese demand for vaccines. "The vaccine market in China is experiencing a much longer than originally expected demand weakness in the market following the unfounded media reports about vaccine safety in China's Shanxi province," the company says in a release. Sinovac release | Report